Arcutis Biotherapeutics Inc (ARQT) concluded trading on Wednesday at a closing price of $7.58, with 4.05 million shares of worth about $30.68 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -10.51% during that period and on Wednesday the price saw a gain of about 9.86%. Currently the company’s common shares owned by public are about 96.79M shares, out of which, 78.91M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 51 times over the past 12 months. They bought 426,138 shares in 23 of the transactions. In 28 selling transactions, insiders dumped 52,564 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the stock later moved at a day high price of 7.64, or with a gain of 9.86%. Stock saw a price change of 32.75% in past 5 days and over the past one month there was a price change of 118.44%. Year-to-date (YTD), ARQT shares are showing a performance of 134.67% which decreased to -54.96% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.76 but also hit the highest price of $17.57 during that period. The average intraday trading volume for Arcutis Biotherapeutics Inc shares is 5.54 million. The stock is currently trading 42.90% above its 20-day simple moving average (SMA20), while that difference is up 95.00% for SMA50 and it goes to 16.24% higher than SMA200.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) currently have 96.79M outstanding shares and institutions hold larger chunk of about 90.14% of that.
The stock has a current market capitalization of $733.67M and its 3Y-monthly beta is at 0.98. It has posted earnings per share of -$5.65 in the same period. It has Quick Ratio of 6.39 while making debt-to-equity ratio of 4.39. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ARQT, volatility over the week remained 11.63% while standing at 12.00% over the month.
Analysts are in expectations that Arcutis Biotherapeutics Inc (ARQT) stock would likely to be making an EPS of -$0.78 in the current quarter, while forecast for next quarter EPS is -$0.8 and it is -$2.59 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.96 which is -$0.48 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$1.18 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 34.98% while it is estimated to increase by 37.60% in next year. EPS is likely to grow at an annualized rate of 9.80% for next 5-years, compared to annual growth of -110.36% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Mizuho on January 03, 2024 offering a Buy rating for the stock and assigned a target price range of between $4 and $8 to it.
